AGL — Agilon Health, Inc. stock price, charts and financials

NYSE·Healthcare·Medical - Care Facilities·USA

Latest market price

89.16

-0.01-0.01%

Overview Short InterestFilings

AGLQT93Agilon Health, Inc.·NYSE

Overview Short InterestFilings

89.16-0.01%

Loading chart...

Signal & projected range

Analyst upgradeHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

INNV+2.06%$10.92 HCSG-0.09%$21.47 ARDT-2.06%$10.48 NUTX-2.58%$208.79 PNTG-1.02%$39.62 AMN-0.84%$34.26 ASTH+0.17%$34.36 SGRY-0.75%$13.25

Snapshot

Index	-	P/E	-	EPS (ttm)	-15.41	Insider Own	-	Shs Outstand	16.68M	Perf Week	-0.68%

Market Cap	1.49B	Forward P/E	48.96	EPS next Y	1.82	Insider Trans	0.00%	Shs Float	11.71M	Perf Month	-4.78%

Enterprise Value	1.33B	PEG	-	EPS next Q	-1.18	Inst Own	-	Short Float	9.22%	Perf Quarter	-21.65%

Income	-251.00M	P/S	0.25	EPS this Y	86.19%	Inst Trans	-	Short Ratio	3.27	Perf Half Y	655.59%

Sales	5.92B	P/B	6.52	EPS next Y	185.55%	ROA	-15.78%	Short Interest	1.08M	Perf YTD	417.77%

Book/sh	13.67	P/C	8.00	EPS next 5Y	-	ROE	-119.35%	52W High	133.03 -32.98%	Perf Year	212.84%

Cash/sh	11.15	P/FCF	-	EPS past 3/5Y	-	ROIC	-90.22%	52W Low	7.48 1091.98%	Perf 3Y	-80.24%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	35.44% 37.25%	Gross Margin	0.00%	Volatility	6.04% 5.89%	Perf 5Y	-88.77%

Dividend TTM	-	EV/Sales	0.23	EPS Y/Y TTM	2.16%	Oper. Margin	-4.48%	ATR (14)	6.28	Perf 10Y	-

Dividend Ex-Date	Nov 16, 2011	Quick Ratio	1.08	Sales Y/Y TTM	-2.34%	Profit Margin	-4.24%	RSI (14)	44.41	Recom	2.72

Dividend Gr. 3/5Y	-	Current Ratio	1.08	EPS Q/Q	116.64%	SMA20	-2.37%	Beta	2.92	Target Price	94.22

Payout	0.00%	Debt/Eq	0.29	Sales Q/Q	7.17%	SMA50	-9.26%	Rel Volume	1.19	Prev Close	89.17

Employees	856	LT Debt/Eq	0.14	Earnings	Nov 03	SMA200	62.26%	Avg Volume	310.82K	Price	89.16

IPO Date	Apr 15, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	622.37% 3.03%	Net Debt/EBITDA	0.32	Volume	369,996	Change	-0.01%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-15-26	Reiterated	RBC Capital	Outperform	$125
Sep-15-26	Upgrade	Bernstein	Market Perform → Outperform	$125
Aug-11-26	Upgrade	Citigroup	Sell → Neutral
Aug-11-26	Reiterated	Wells Fargo	Overweight	$141 → $146
Aug-06-26	Reiterated	Robert W. Baird		$35 → $116
Aug-06-26	Reiterated	Truist Securities	Hold	$6.50 → $112
Aug-06-26	Reiterated	Barclays	Equal Weight	$81 → $111
Jul-23-26	Downgrade	Citigroup	Neutral → Sell
Jul-13-26	Reiterated	Wells Fargo	Overweight	$72 → $141
May-26-26	Upgrade	Barclays	Underweight → Equal Weight	$81

Latest News· Times ET

Sep-15-26

Sep-15-2604:55AM

This Ulta Beauty Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For TuesdayBenzinga

Sep-10-26

Sep-10-2605:00AM

agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACObusinesswire.com

Sep-04-26

Sep-04-2602:00PM

Insiders Are Buying These 2 Stocks — Should You Take the Hint?Yahoo

Aug-28-26

Aug-28-2606:51AM

agilon health (AGL) Price Target Increased by 44.58% to 111.20Fintel

06:40AM

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?zacks.com

Aug-27-26

Aug-27-2612:05PM

agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conferencebusinesswire.com

Aug-24-26

Aug-24-2605:57AM

JP Morgan Maintains Underweight on Agilon Health, Raises Price Target to $85Benzinga

Aug-20-26

Aug-20-2612:05PM

agilon health to Participate in Upcoming Conferencesbusinesswire.com

Aug-19-26

Aug-19-2604:14PM

Q2 Earnings Highlights: agilon health (NYSE:AGL) Vs The Rest Of The Outpatient & Specialty Care StocksYahoo

Aug-12-26

Aug-12-2606:41AM

Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year?zacks.com

Aug-11-26

Aug-11-2602:31PM

Australia's AGL Energy logs nearly 2% fall in annual profitreuters.com

05:06AM

Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $146Benzinga

Aug-07-26

Aug-07-2606:07AM

agilon health: The Q2 Inflection Is Realseekingalpha.com

Aug-06-26

Aug-06-2604:14AM

agilon health, inc. (AGL) Q2 2026 Earnings Call Transcriptseekingalpha.com

12:04AM

Agilon Health Q2 Earnings Call Highlightsmarketbeat.com

Company

Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 2/18/2021	FY 2019 12/31/2019
Total Revenue	5,919	5,933	6,061	—	—	—	—	—
Cost of Goods Sold Incl. D&A	5,920	6,121	6,056	—	—	—	—	—
Gross Profit	-1	-189	5	—	—	—	—	—
Selling, General and Administrative Excl. Other	259	239	269	—	—	—	—	—
Research and Development	0	0	0	—	—	—	—	—
Other Operating Expense	6	-7	28	—	—	—	—	—
Operating Income	-265	-421	-292	—	—	—	—	—
Interest Expense	4	7	6	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	18	24	49	—	—	—	—	—
Net Income Before Taxes	-251	-404	-249	—	—	—	—	—
Income Taxes	1	1	1	—	—	—	—	—
Consolidated Net Income	-251	-405	-260	—	—	—	—	—
Net Income From Continuing Operations	-251	-405	-250	—	—	—	—	—
Net Income	-251	-405	-260	—	—	—	—	—
EPS (Recurring)	-15.38	-24.50	-15.75	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-15.38	-24.50	-15.75	—	—	—	—	—
EPS (Diluted)	-15.41	-24.50	-15.75	—	—	—	—	—
EBITDA	-234	-369	-218	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	0.26	0.05	0.13	—	—	—	—	—
Gross Margin	-0.02	-3.19	0.08	—	—	—	—	—
Operating Margin	-4.48	-7.10	-4.82	—	—	—	—	—
Net Margin	-4.24	-6.83	-4.29	—	—	—	—	—
Shares Outstanding	17	17	16	—	—	—	—	—
Market Capitalization	1,516	293	760	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shaker Benjamin	Chief Markets Officer	Mar 02 '26	Buy	0.60	500,000	301,050	1,367,674	Mar 03
Wulf John William	Director	Nov 12 '25	Buy	0.63	81,000	50,941	365,857	Jan 30
Schwaneke Jeffrey A.	Chief Financial Officer	Nov 29 '23	Buy	11.22	44,600	500,412	31,931	Apr 03
Sell Steven	CEO & President	Mar 14 '25	Buy	0.00	42,426	0	370,873	Mar 18
Shaker Benjamin	Chief Markets Officer	Mar 14 '25	Buy	0.00	11,786	0	461,201	Mar 18
Venkatachaliah Girish	Chief Technology Officer	Mar 14 '25	Buy	0.00	9,429	0	158,431	Mar 18
McLoughlin Karen	Director	Dec 13 '24	Buy	2.20	25,000	55,085	73,166	Dec 13
Battaglia Silvana	Director	Dec 11 '24	Buy	2.01	25,062	50,269	66,144	Dec 13
MCKENZIE DIANA	Director	Dec 09 '24	Buy	2.20	7,500	16,489	58,819	Dec 11
Wulf John William	Director	Dec 05 '24	Buy	2.18	45,000	98,145	206,133	Dec 11
MCKENZIE DIANA	Director	Nov 25 '24	Buy	2.28	12,500	28,474	51,319	Dec 11
Sell Steven	CEO & President	Sep 12 '24	Buy	3.36	20,000	67,188	67,590	Sep 16
Kornitzer Benjamin	Chief Med. & Quality Officer	Mar 14 '24	Buy	0.00	5,434	0	63,941	Mar 18
Venkatachaliah Girish	Chief Technology Officer	Mar 14 '24	Buy	0.00	5,434	0	41,833	Mar 18
Shaker Benjamin	Chief Markets Officer	Mar 14 '24	Buy	0.00	274,455	0	353,998	Mar 18

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.